Select Medical (SEM) Q1 2026 Earnings Transcript

Select Medical reported 5% revenue growth but a 6.5% decline in adjusted EBITDA to $141 million, with EPS of $0.35 versus $0.44 a year ago. Management reaffirmed full-year 2026 guidance and highlighted continued bed expansion, but margins were pressured by Medicare Advantage denials and weaker critical illness recovery performance. The company also advanced its take-private deal, with unaffiliated shareholders set to receive $16.50 per share in cash and HSR review already complete.

Analysis

The take-private effectively turns SEM into a short-duration event-driven instrument with a capped upside and binary closing risk. The real market color is not the headline cash price, but the financing structure: an incremental $1B term loan at SOFR+300 bps implies a levered sponsor model that is willing to underwrite the asset on normalized reimbursement and bed-expansion cash flows, which supports the view that current segment-level margin pressure is cyclical and operational rather than structural. That also means public holders are unlikely to get paid for an equity-duration recovery; the value transfer is being monetized by sponsors, not by a rerating in the listed stock.

The second-order issue is that Medicare Advantage deterioration is not evenly distributed. It is hitting the higher-acuity hospital businesses first, which are the assets the buyer is effectively taking off the market before any broader reimbursement normalization can show up. If conversion stays weak into the next two quarters, the public equity may still hold near deal value, but the operating read-through for post-acute peers is negative because it suggests tighter payer behavior is becoming a volume headwind rather than a simple mix issue.

The most interesting contrarian angle is that management’s optimism on CMS rate updates may be less valuable than it sounds. A 2-3% reimbursement tailwind is modest relative to the revenue lost from MA denial pressure and outpatient rationalization costs, so the path to margin recovery depends more on mix repair and capacity discipline than on the rule cycle. For competitors, that increases the odds of clinic closures, bed rationalization, and share consolidation in weaker geographies over the next 6-12 months.

Net: this is a low-volatility spread, not a fundamental long. The main risk to the deal is regulatory or financing disruption over the next few months; beyond that, the key catalyst for the broader group is whether MA denial trends worsen into the next reporting period, which would pressure post-acute multiples across the peer set.

Key Decisions for Investors

• If long SEM, treat it as a deal-spread trade only: buy on any pullback toward a modest discount to $16.50 and exit into closing; expected upside is limited, while break risk is binary over the next 1-3 months.
• Short a basket of post-acute / rehab operators against CMS if MA denials continue to widen over the next 1-2 quarters; the cleaner expression is long CMS, short SEM peers with similar reimbursement sensitivity, because reimbursement tailwinds are being overwhelmed by payer friction.
• Consider a short-dated SEM put spread only if the spread widens materially on regulatory or financing headlines; risk/reward is attractive only when implied volatility is cheap relative to deal failure probability.
• For longer-only healthcare exposure, rotate away from outpatient-heavy names with weak local markets and toward higher-quality operators with better payer mix and scale; the next 6-12 months favor consolidation winners over marginal clinics.
• Watch MA utilization and denial commentary into the next print as the real catalyst; if the trend worsens, use it to fade peer multiples rather than SEM, since the stock is already anchored by deal terms.